litigation
confidence high
sentiment positive
materiality 0.65
REGENXBIO settles patent litigation with Sarepta for $39M payment
REGENXBIO Inc.
- Sarepta will pay $39.0 million to REGENXBIO within 10 days of settlement effective date (Sept 23, 2026).
- Settlement resolves all patent infringement litigation over U.S. Patent Nos. 10,526,617 and 11,680,274 related to ELEVIDYS (SRP-9001).
- Parties terminate litigation with prejudice; REGENXBIO and UPenn release current claims and covenant not to sue on AAVrh74-based products.
- Covenant covers existing ELEVIDYS form and AAVrh74 capsid sequence, but does not extend to other gene therapy aspects.